Sunesis Licenses FBLD Technology To Carmot
Carmot is expected to use the FBLD technology, called ‘Chemotype Evolution,’ for identifying drug candidates in a broad range of therapeutic areas, including inflammatory, metabolic, and neurodegenerative diseases.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.